1. Home
  2. MRM vs SYBX Comparison

MRM vs SYBX Comparison

Compare MRM & SYBX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

MRM

MEDIROM Healthcare Technologies Inc.

HOLD

Current Price

$1.70

Market Cap

15.8M

ML Signal

HOLD

Logo Synlogic Inc.

SYBX

Synlogic Inc.

HOLD

Current Price

$0.58

Market Cap

15.2M

Sector

Health Care

ML Signal

HOLD

Company Overview

Basic Information
Metric
MRM
SYBX
Founded
2000
N/A
Country
Japan
United States
Employees
N/A
N/A
Industry
Other Consumer Services
Biotechnology: Pharmaceutical Preparations
Sector
Consumer Discretionary
Health Care
Exchange
Nasdaq
Nasdaq
Market Cap
15.8M
15.2M
IPO Year
2020
N/A

Fundamental Metrics

Financial Performance
Metric
MRM
SYBX
Price
$1.70
$0.58
Analyst Decision
Analyst Count
0
0
Target Price
N/A
N/A
AVG Volume (30 Days)
97.3K
193.9K
Earning Date
05-22-2026
03-05-2026
Dividend Yield
N/A
N/A
EPS Growth
N/A
N/A
EPS
0.04
N/A
Revenue
$55,915,220.00
N/A
Revenue This Year
N/A
N/A
Revenue Next Year
N/A
N/A
P/E Ratio
$40.25
N/A
Revenue Growth
12.79
N/A
52 Week Low
$0.34
$0.56
52 Week High
$4.45
$1.96

Technical Indicators

Market Signals
Indicator
MRM
SYBX
Relative Strength Index (RSI) 30.28 16.83
Support Level $1.69 $1.17
Resistance Level $1.78 $1.19
Average True Range (ATR) 0.09 0.06
MACD -0.02 -0.03
Stochastic Oscillator 2.94 5.63

Price Performance

Historical Comparison
MRM
SYBX

About MRM MEDIROM Healthcare Technologies Inc.

MEDIROM Healthcare Technologies Inc provides health services. The company is a franchiser and operator of healthcare salons and operates in segments namely Relaxation Salon, Digital Preventative Healthcare, and Luxury Beauty Segment. The company generates a majority of its revenue from the Relaxation Salon business segment. Geographically, the company generates a maximum share of its revenue from Japan.

About SYBX Synlogic Inc.

Synlogic Inc is a biopharmaceutical company focuses on rare metabolic disorders, with a lead program in phenylketonuria (PKU) and homocystinuria (HCU). The company's pipeline includes therapeutics for enteric hyperoxaluria, gout, and cystinuria. Using a proprietary approach, the company engineer GI-restricted, oral medicines from well-characterized probiotics. These drug candidates target specific biological pathways, leveraging Escherichia coli Nissle 1917 for consistency and safety. Engineered to be non-colonizing and reversible, the company offer oral administration, simplifying shipping and storage. The company operates in one segment-discovery and development of Synthetic Biotics-pioneering transformative treatments for serious diseases.

Share on Social Networks: